The Repeatability of Forced Expiratory Volume Measurements in Adults with Cystic Fibrosis

Chest

Volumn 125, Issue 1, 2004, Pages 150-155

  Stanbrook, Matthew B ^b,c,e   Corey, Mary ^c,d   Tullis, D Elizabeth ^a,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Adult; Cystic fibrosis; Forced expiratory volume; Reproducibility of results; Respiratory function tests

Indexed keywords

MUCOLYTIC AGENT;

ADOLESCENT; ADULT; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG DISEASE; MALE; MEASUREMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; REPRODUCIBILITY; SPIROMETER; TEACHING HOSPITAL; UNIVERSITY;

EID: 1642534562     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.1.150     Document Type: Article

References (21)

1. Davis PB. Clinical pathophysiology and manifestations of lung disease. In: Yankaskas JR, Knowles MR, eds. Cystic fibrosis in adults. Philadelphia, PA: Lippincott-Raven Publishers, 1999; 45-67
2. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187-1191
3. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-1218
4. Hruby J, Butler J. Variability of routine pulmonary function tests. Thorax 1975; 30:548-553
5. Pennock BE, Rogers RM, McCaffree DR. Changes in measured spirometric indices: what is significant? Chest 1981; 80:97-99
6. Lewinsohn HC, Capel LH, Smart J. Changes in forced expiratory volumes throughout the day. BMJ 1960; 1:462-464
7. Cooper PJ, Robertson CF, Hudson IL, et al. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol 1990; 8:16-22
8. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
9. Tullis DE, Corey M, Dabora R, et al. A double blind, placebo-controlled dose-escalating, tolerability study of inhaled recombinant gelsolin in cystic fibrosis [abstract]. Pediatr Pulmonol 1998; S15:A265
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310
11. Chinn S. Repeatability and method comparison. Thorax 1991; 46:454-456
12. Chinn S. The assessment of methods of measurement. Stat Med 1990; 9:351-362
13. 1. Thorax 1983; 38:662-667
14. McCarthy DS, Craig DB, Cherniack RM. Intraindividual variability in maximal expiratory flow-volume and closing volume in asymptomatic subjects. Am Rev Respir Dis 1975; 112:407-411
15. Cochrane GM, Prieto F, Clark TJH. Intrasubject variability of maximal expiratory flow volume curve. Thorax 1977; 32:171-176
16. Chinn S, Britton JR, Burney PGJ, et al. Estimation and repeatability of the response to inhaled histamine in a community survey. Thorax 1987; 42:45-52
17. Spencer DA, Marshall T, Weller PH, et al. A superior method for assessing the reproducibility of pulmonary function measurements [abstract]. Am Rev Respir Dis 1992; 145:A253
18. Enright P. Reporting the reproducibility of spirometry results. Am Rev Respir Dis 1992; 146:1367-1368
19. Enright PL, Johnson LR, Connett JE, et al. Spirometry in the Lung Health Study: methods and quality control. Am Rev Respir Dis 1991; 143:1215-1223
20. 1 and peak expiratory flow rates among normal and asthmatic subjects. Thorax 1994; 49:775-780
21. Nickerson BG, Lemen RJ, Gerdes CB, et al. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 1980; 122:859-866